首药控股(688197) - 2024 Q1 - 季度财报

Financial Performance - The company reported a net loss attributable to shareholders of RMB 53,307,597.39 for the first quarter of 2024[4]. - The company reported a net loss of RMB 859,071,528.03, compared to a loss of RMB 805,763,930.64 in the previous period[16]. - The net loss for Q1 2024 was 53,307,597.39 RMB, compared to a net loss of 47,087,606.68 RMB in Q1 2023, indicating a deterioration of about 13.5%[18]. - Basic and diluted earnings per share for Q1 2024 were both -0.36 RMB, compared to -0.32 RMB in Q1 2023[19]. - The company’s total comprehensive loss for Q1 2024 was CNY 52,956,251.73, compared to CNY 46,837,348.72 in Q1 2023, reflecting a decline of approximately 13.4%[26]. Revenue and Expenses - Total revenue for Q1 2024 was 56,883,837.15 RMB, an increase from 47,801,030.22 RMB in Q1 2023, representing a growth of approximately 19.5%[17]. - Operating costs for Q1 2024 were 56,883,837.15 RMB, up from 47,801,030.22 RMB in Q1 2023, indicating an increase of about 19.5%[17]. - R&D expenses rose to 53,553,272.74 RMB in Q1 2024 from 48,919,643.08 RMB in Q1 2023, reflecting an increase of approximately 9.3%[17]. - Research and development expenses totaled RMB 53,553,272.74, representing an increase of 9.47% compared to the previous period[4]. Cash Flow - The company reported a net cash flow from operating activities of RMB -45,250,824.29, indicating increased clinical trial expenses[4]. - Cash flow from operating activities for Q1 2024 was -45,250,824.29 RMB, worsening from -42,465,600.10 RMB in Q1 2023[21]. - Cash flow from investing activities generated a net inflow of 50,434,148.36 RMB in Q1 2024, compared to a net outflow of -1,535,049.00 RMB in Q1 2023[21]. - The cash and cash equivalents increased by $4,058,933.97 in Q1 2024, contrasting with a decrease of -$43,836,749.37 in the same period last year[29]. Assets and Liabilities - Total assets decreased by 4.15% to RMB 1,065,904,344.95 from the end of the previous year[5]. - The total current assets decreased to RMB 826,584,930.25 from RMB 982,252,710.03, representing a reduction of about 15.9%[15]. - The total liabilities increased to RMB 98,259,784.15 from RMB 91,158,853.63, indicating an increase of approximately 7.4%[16]. - The company's equity attributable to shareholders decreased to RMB 967,644,560.80 from RMB 1,020,952,158.19, a decline of about 5.2%[16]. - The total liabilities and equity amounted to 1,065,904,344.95 RMB as of March 31, 2024[22]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 3,576[9]. - The largest shareholder, Li Wenjun, holds 49.05% of the shares, totaling 72,953,101 shares[9]. Inventory and Accounts Payable - The company experienced a significant increase in inventory by 260.71% due to the purchase of related experimental controls for Phase III trials[7]. - The accounts payable increased to RMB 88,157,873.54 from RMB 75,842,532.45, reflecting an increase of about 16.5%[16]. - The company reported a significant increase in inventory, rising to RMB 918,381.72 from RMB 254,602.82, which is an increase of approximately 261.5%[15]. Other Financial Metrics - The weighted average return on equity was -5.36% for the reporting period[4]. - The company recorded a fair value change gain of 2,402,426.44 RMB in Q1 2024, compared to a gain of 432,500.00 RMB in Q1 2023[18]. - The company reported a financial income of CNY 2,624,811.32 in Q1 2024, down from CNY 6,202,265.13 in Q1 2023, a decrease of about 57.7%[26]. Corporate Governance - The company did not report any cash inflow from financing activities in Q1 2024[29]. - The company is not applying new accounting standards for the first time in 2024, as indicated in the report[30]. - The report was published by the board of directors of Shouyao Holdings (Beijing) Co., Ltd. on April 26, 2024[30].